Regulation FD Disclosure (Form 8-K)

Item 7.01 Regulation FD.

As Nektar Therapeutics (the "Company") prepares for analyses of data (the "Maintenance Data") from the 36-week maintenance period of its Phase 2b REZOLVE-AD study of rezpegaldesleukin in patients with moderate-to-severe atopic dermatitis, the Company is entering a quiet period beginning January 27, 2026 and continuing until the public announcement of the data. The implementation of the quiet period is consistent with the Company's prior quiet periods pertaining to the Phase 2b REZOLVE studies and planned data disclosures. The Company's next planned investor communication is expected in February 2026 at the time of the presentation of the Maintenance Data.

The information contained in Item 7.01 of this Current Report on Form 8-K is being furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.